Clinical Trials
Accentia's Currently Ongoing Clinical Trials
BIOVAXID™Vaccine for Non-Hodgkin's Lymphoma
BIOVAXID™ Phase III Study #301 is currently enrolling patients with indolent (slow growing) follicular Non-Hodgkin's Lymphoma.
To find physicians near your location that are participating in the clinical trial, please call our toll-free number for information:
1-877-654-6052
Before the FDA will approve a drug, the sponsoring company must conduct several clinical studies. The studies are done in phases to determine what the side effects of the drug are and how effective it is in treating the disease. The earliest studies (pre-clinical, meaning in the lab before they are given to people) are to determine if the drug works in the way it was thought to work. The pre-clinical phase looks at the safety of the drug before it is given to anyone. Phase I trials evaluate the safety of the new therapy in a small number of human subjects. Phase II trials investigate the new therapy's safety in a larger group of humans and will determine the most effective dose and duration.
BIOVAXID™ is currently undergoing Phase III clinical trials, which is the last part of the clinical development process. In these studies, a large number of patients are treated with the dose regimen that was identified in the earlier trials in order to prove that the new medication is both safe and effective for its intended therapy. When the clinical trials are complete, these data will be submitted to the FDA for review. When the FDA has completed its review and makes a determination that the safety and efficacy have been satisfactorily proven, it approves the new drug.
For more information, please visit our page on BIOVAXID™ Immunotherapy Vaccine for Non-Hodgkin's Lymphoma
To find answers to the most frequently asked questions on Non-Hodgkin's Lymphoma, please visit our Non-Hodgkin's Lymphoma FAQ or our Physician's Information Section on BIOVAXID™.
Enrollment
|
